Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Durvalumab

Diabetes ketoacidosis and hypothyroidism: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Ali A, et al. New horizon to minimize fatal adverse events of immune checkpoint inhibitors: Durvalumab-induced diabetes ketoacidosis as an example. Diabetic Medicine 40 (Suppl. 1): 7, Apr 2023. Available from: URL: http://doi.org/10.1111/dme.15047 [abstract] Ali A, et al. New horizon to minimize fatal adverse events of immune checkpoint inhibitors: Durvalumab-induced diabetes ketoacidosis as an example. Diabetic Medicine 40 (Suppl. 1): 7, Apr 2023. Available from: URL: http://​doi.​org/​10.​1111/​dme.​15047 [abstract]
Metadaten
Titel
Durvalumab
Diabetes ketoacidosis and hypothyroidism: case report
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41427-9

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Antineoplastics

Case report

Elasomeran

Case report

Epinephrine

Case report

Multiple drugs